Taiwan ACS Registry – Focus on Antiplatelet Therapy


Jun-Jack Cheng, MD, PhD

President of Taiwan Society of Cardiovascular Interventions Shin Kong Hospital, Taipei, Taiwan

Jack JCR 2013

Taiwan (Study Design (2008-2010)


- Actual/ Target patient number: 3183 / 3000
- Site number: 39
 - Each site will recruit 50~200 patients (competitive recruitment)
- Visit schedule: 5 visits per patient



Treatment: This is a non-interventional registry



3183 patients were enrolled from October 2008 to January 2010.



* atypical chest pain: 15; stable angina: 15; CHF: 10; arrhythmia: 5; pericardial disease= 1; Prinzmetal angina: 1; myocardial failure: 1; pneumonia and acute resp. failure: 1; complicated 2nd AV block: 1; acute cholangitis: 1; death: 1




	Taiwan ACS FS
	N=3183
Mean age ± SD (yrs)	63 ± 14
Female gender (%)	22
Hypertension (%)	64
Dyslipidemia (%)	39
Diabetes (%)	36
Prior MI (%)	10
Prior CHF (%)	5
Prior PCI (%)	17
Prior CABG (%)	3




	Taiwan ACS FS
	N=3183
Cardiac angiogram (%)	94
Reperfusion in STEMI (%)	82
PCI (%)	84
CABG (%)	3





Time to in-hospital procedures is expressed in median value



P<0.01 for all comparisons between STEMI, Non-STEMI and UA



Treatments at Discharge


	STEMI	NSTEMI	UA
n	13,862	11,316	12,509
	%	%	%
ACE inhibitors	67	56	52
Aspirin	92	89	88
β-blockers	78	76	72
Ca ²⁺ blockers	10	20	31
Statins	63	59	57
Warfarin	8	7	7



- Total no. of patient data analyzed: 2544 (80%)
- Classified by discharge diagnosis:
 - **STEMI (n=1358, 53.4%)**
 - Non-STEMI (n=844, 33.2%)
 - Unstable Angina (n=322, 12.7%)
 - Others (n=20, 0.8%)



12-Month Medications – Total patients by diagnosis



* P<0.01 for comparison between STEMI, Non-STEMI and UA

Outcomes from Enrollment to 12-Month

Cumulative event (%)	STEMI	Non-STEMI	UA	Total [#]
Death	6.1%	10.1%	6.2% *	7.5%
Rehospitalization	41.9%	44.5%	37.8%	42.3%
Stroke	1.6%	2.5%	2.2%	2.0%
MI	4.7%	6.4%	0.9% *	4.8%
Repeat revasc.	7.3%	6.6%	7.5%	7.1%
PCI	18.9%	16.8%	14.8%	17.7%
CABG	1.0%	2.6%	1.6% *	1.6%
Death/MI/Stroke	11.1%	16.8%	8.0% *	12.7%
Any of the above	44.8%	48.0%	40.5%	45.4%


excluding "other" diagnosis

rc Registry

| | |

* P<0.01 for comparison between STEMI, Non-STEMI and UA





Predictors of 12-Month Death/MI/Stroke

۲

ACS Registry

Variable		OR#	95% CI	P-value
Medical history				
	Chronic renal failure	4.54	2.62, 7.85	<0.01
	PAD	2.43	1.38, 4.29	<0.01
	Prior heart failure	1.93	1.31, 2.86	<0.01
	History of AF	1.68	1.02, 2.76	0.04
	Cerebrovascular accident	1.49	1.07, 2.07	0.019
	Diabetes	1.3	1.02, 1.65	0.033
In-hospital proc	edure/event			
	In-hospital bleeding	3.87	2.14, 6.99	<0.01
	New-onset ventricular			
	arrhythmia	3.43	2.28, 5.16	<0.01
	LVEF (abnormal)	2.16	1.64, 2.84	<0.01
	New-onset atrial fibrillation	1.98	1.17, 3.35	0.011
	Angiogram	1.4	1.05, 1.89	0.024
<u>Final diagnosis</u>	NSTEMI	1.38	1.09, 1.76	<0.01
<u>Medications</u>				
	Any antiplatelet therapy			
	discontinuation	1.94	1.44, 2.63	<0.01
	Aspirin and clopidogrel			
	< 9 months	1.5	1.04, 2.17	0.031

Statistical method: Logistic regression #Odds ratio (OR) were adjusted for age and sex.

Predictors of 12-Month Death/MI/Stroke

Variable		OR#	95% CI	P-value
<u>Risk factor</u>	Family history	0.61	0.40, 0.92	0.019
Procedures				
	PCI	0.71	0.53, 0.94	0.017
	Stenting	0.59	0.45, 0.76	<0.01
	DES only	0.55	0.39, 0.78	<0.01
Medications				
	ACE/ARB at discharge	0.66	0.48, 0.91	0.01
	Beta-blocker at discharge	0.65	0.51, 0.83	<0.01
	Statin at discharge	0.65	0.51, 0.83	<0.01
	Aspirin at discharge	0.35	0.27, 0.45	<0.01
	Clopidogrel at discharge	0.34	0.26, 0.44	<0.01

Statistical method: Logistic regression #Odds ratio (OR) were adjusted for age and sex.

۲

PC Registry




STEMI were younger, more likely to be men and had poorer left ventricular function with a higher incidence of cardiac death compared to patients with NSTEMI

	STEMI (n=5,110)	NSTEMI (n=3,315)	р
12-month MACE, n (%)			
Cardiac death	630 (12.3)	315 (9.5)	0.009
Non-cardiac death	67 (1.3)	61 (1.8)	0.681
Myocardial infarction	51 (1.0)	63 (1.9)	0.072
Repeat PCI	389 (7.6)	210 (6.3)	0.110
Target vessel revascularization	69 (1.5)	42 (1.4)	0.516
Non-target vessel revascularization	190 (3.7)	94 (2.8)	0.227
Target lesion revascularization	138 (2.7)	79 (2.3)	0.574
Coronary artery bypass grafting	25 (0.5)	27 (0.8)	0.132
Composite MACE	1162 (22.7)	676 (20.4)	0.121
	1		

PCI: percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, MACEs: major adverse cardiac events



The in-hospital and 1-month survival rates were higher in patients with NSTEMI than in patients with STEMI. However, 12-month survival rate was not different between patients with NSTEMI and STEMI.




Doo Sun Sim, et al. Korean Circ J 2009;39:297-303

Taiwan () ACS Registry PACIFC registry (Japan)

More patients with STEMI tended to receive DAPT than NSTE-ACS. only 62.9% and 50.5% of patients continued to receive DAPT after 1 year and 2 years.

Table 2. Hospital and Post-Discharge Treatments						
		Hos	After discharge			
Treatment	Total (n=3,597)	STEMI (n=2,135)	NSTE-ACS (n=1,462)	P-value [†]	1-year total (n=3,351)	2-year total (n=3,228)
PCI (total)	93.5	95.6	90.4	<0.001	-	-
POBA	16.6	15.6	18.1	0.128		
BMS	62.2	73.4	45.9	<0.001	-	-
DES	30.2	21.0	43.5	<0.001	-	-
PCI success rate [‡]	93.9	92.1	96.7	<0.001	-	-
CABG	2.4	1.0	4.4	<0.001	-	-
Pharmacological therapics, %						
Anti-platelet agents (total)	99.3	99.3	99.3	0.948	92.2	84.7
Monotherapy	6.7	5.0	9.2	<0.001	29.3	34.2
DAPT	87.7	88.5	86.7		62.9	50.5
DAPT to monotherapy	4.9	5.9	3.4			
Oral anticoagulants	10.5	11.7	8.8	0.005	9.1	8.8
Anti-hypertensives agents	91.6	93.5	88.9	<0.001	86.3	79.4
ACEI/ARBs	78.5	83.1	71.8	<0.001	70.8	63.6
β-blockers	49.5	54.7	42.0	<0.001	46.9	42.8
Calcium inhibitors	28.8	20.6	40.9	<0.001	33.8	33.5
Anti-arrhythmic drugs	8.9	11.2	5.4	<0.001	4.1	3.8
Statins	77.8	80.4	73.9	<0.001	75.0	69.5
PPIs	57.8	62.7	50.6	<0.001	50.9	47.8
Oral anti-diabetic drugs	22.5	22.0	23.2	0.408	23.9	22.3

Taiwan (a) ACS Registry ACACIA registry (Australia)




Chew D, et al. Med J Aust 2008; 188(12):691-7




After Discharge to 1 yr	All Patients $(n = 4,220)$	QMI (n = 1,140)	NQMI (n = 1,350)	UAP (n = 1,730)	p Value*
Death	7.2%	6.5%	10%	5.4%	< 0.0001
Nonfatal myocardial infarction	2.9%	2.7%	3.7%	2.6%	0.17
UAP '	8.0%	5.8%	6.4%	11%	< 0.0001
Angiography	14%	15%	13%	14%	0.40
Percutaneous coronary intervention	6.8%	6.6%	6.6%	7.2%	0.82
Coronary bypass surgery	3.9%	4.3%	4.3%	3.3%	0.33

Yan AT et al. Am J Cardiol 2004;94:25–29










Recommended therapies include aspirin, clopidogrel, beta-blocker, statin, ACEI or ARB

Antiplatelet Medications Use




ACS Registry Reasons of Clopidogrel Discontinuation

Taiwan 💿

Early discontinuation of					
clopidogrel within 9 months					
(n=1162)					
BNHI regulations	41.0%				
Doctor decision	25.4%				
Unknown	16.2%				
BMS implantation	5.0%				
Death	3.4%				
Cost	3.0%				
Adverse events	1.7%				
Change to other antiplatelet	1.3%				
Patient decision	1.3%				
Surgery	0.5%				
DES implantation	0.3%				
Warfarin use	0.3%				
Bleeding	0.3%				
Co-morbidities	0.3%				

Taiwan (\odot)Death according to Duration of DAPTACS Registry \geq 9 months vs < 9 months – Overall ACS</th>




Death/MI/Stroke according to duration of DAPT


\geq 9 months vs < 9 months – Overall ACS

۲

A P C Registry







Statistical method: Logistic regression #Odds ratio (OR) were adjusted for age and sex.



- 7.5% of ACS patients will die within one year.
 - Mortality was higher in NSTEMI (10.1%) than UA (6.2%) and STEMI (6.1%).
- Usage of evidence based medications were sub-optimal.
 - In particular, DAPT: clopidogrel + aspirin declined dramatically from 75% at discharge to 25% at 1 year, replaced by aspirin only.
- Usage of evidence-based medications is associated with a reduction in 12-month clinical events (death/MI/stroke).
- DAPT for 9 months or longer was associated with lower 1-year mortality.
- Reasons for clopidogrel discontinuation were mainly BNHI regulations (41%) and doctor decision (25%).

D2BALLIANCE – Taiwan Experience



Taiwan Joint Commission on Hospital Accreditation

Jack, TTT 2010

Taiwan Hospital Accreditation 2011

 ECG Cardiac enzymes LDL 	DX	TX	 DAP β-blocker PPCI RASI Statin
 In-Hospital Mortality Readmission (%) Return to ICU (24H) Return to ES (72H) 	FU	ED	 Rehabilitation Mx education Smoking cessation





Observational Study of Dual Antiplatelet Therapy in Taiwanese Patients with Acute Coronary Syndrome Undergoing Stent Placement


2012-2013

Baseline Characteristics

		ACS-FS Registry			
Variable	STEMI	NSTEMI	UA	Total	Total
Age (years)*	59.3 (13.3)	64.7 (13.5)	64.9 (12.2)	61.5 (13.5)	63.1 (13.6)
Gender (male)	84%	76%	88%	82%	78%
BMI (kg/m²)*	25.7 (3.8)	25.2 (4.1)	25.8(3.1)	25.5 (3.8)	25.4 (3.9)
Killip Class					
1	65.9%	60.2%	79.2%	65.1%	61.4%
Ш	18.4%	16.7%	16.7%	17.8%	18.0%
III/IV	15.7%	18.5%	4.2%	17.1%	20.6%




Final Diagnosis






DTB – STEMI



* expressed in median value

DTB: 1st Door to Balloon for primary PCI

Taiwan 💿




DTB = 1st Door to Balloon for primary PCI

In-hospital Medications Use

۲

C Registry



* ACS-FS Registry: medications use within the first 24 hours


ACS Registry STENT Registry: Antiplatelet Use - Plavix

Taiwan 💿

Variable	Total	STEMI	NSTEMI	UA
Loading Dose given %	96.2%	95.5%	98.1%	94.6%
- median dose (mg)	300	300	300	300
- given before PCI %				
> 24hrs	21.6%	6.4%	46.4%	36.5%
12-24hrs	7.6%	2.7%	14.6%	15.4%
2-12hrs	10.0%	9.1%	10.0%	15.4%
< 2 hrs	52.9%	76.0%	23.8%	5.8%
- on table	4.0%	2.4%	1.3%	21.2%
- after PCI	3.8%	3.4%	4.0%	5.8%



In-Hospital Outcomes





- More than 50% of subjects are STEMI patients.
- Compared with the data of ACS-FS registry, the median DTB time is shortened and the medication prescription rates are increasing but still sub-optimal from guideline recommendation.
- The study population is "ACS patients with <u>stent placement</u> are treated with Aspirin and Plavix after intervention". ACS patients with cardiac angiography or POBA only are not eligible.
- Strongly recommend to recruit eligible patients in a <u>consecutive</u> manner to avoid selection bias.



TAIWAN TRANSCATHETER THERAPEUTICS

LIVE COURSE

January 11-12, 2014 NTUH International Convention Center Taipei, Taiwan

Course Directors

Jun-Jack Cheng, MD President, TSCI

+Chang Hsleh, MD Chairman, Scientific Committee, TSCI

Wen-Lieng Lee, MD Secretary General, TSCI

